Navigation Links
ISTA Pharmaceuticals Announces Preliminary, Unaudited Revenue of $110.6 Million in 2009
Date:2/1/2010

IRVINE, Calif., Feb. 1 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced it had exceeded the $100 million revenue threshold with preliminary, unaudited net revenues of $110.6 million for the year ended December 31, 2009.  ISTA's continued growth of its Xibrom™ (bromfenac ophthalmic solution) 0.09% and Istalol® (timolol maleate ophthalmic solution) 0.5% franchises, in addition to initial orders for ISTA's recently approved treatment for allergic conjunctivitis, Bepreve™ (bepotastine besilate ophthalmic solution) 1.5%, led to the 33% increase in revenue as compared to 2008 net revenue.

The Company ended 2009 with approximately $53.7 million in cash, which includes a $13 million draw down in December 2009 under ISTA's revolving line of credit with Silicon Valley Bank.

All statements relating to the Company's 2009 financial results contained in this release are preliminary and may change based on the completion of the Company's annual financial audit.  

2010 Guidance to be Announced February 9, 2010

ISTA's Chief Executive Officer, Vicente Anido, Jr., Ph.D., will discuss 2010 financial guidance during his presentation at the 12th Annual BIO CEO & Investor Conference.  Dr. Anido's presentation will take place on Tuesday, February 9 at 1:00 p.m. Eastern, and the Company will have a live webcast feed of the presentation available on the ISTA website, www.istavision.com, and archived until March 9, 2010.  In conjunction, the Company will issue a press release with the guidance.

Full 2009 Financial Results to be Announced on February 23, 2010

After market close on February 23, 2010, the Company will issue full financial results for 2009.  In conjunction, ISTA will host a conference call to discuss the 2009 results, as well as review 2010 guidance and the Company's product development pipeline.

Date: Tuesday, February 23, 2010

Time: 5:00 p.m. Eastern Time

Conference call access:

Internet: www.istavision.com

Domestic dial-in: 866-713-8395

International dial-in: 617-597-5309

Passcode: 78279134

To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the replay is 50811924. This conference call also will be webcast live and archived on ISTA's website until March 23, 2010.

Xibrom™ (bromfenac ophthalmic solution) 0.09%, Istalol® (timolol maleate ophthalmic solution) 0.5%, and Bepreve™ (bepotastine besilate ophthalmic solution) 1.5% are trademarks of ISTA Pharmaceuticals.

Full prescribing information for Bepreve™ is available on ISTA Pharmaceuticals' website at http://www.istavision.com/pdf/Bepreve_insert.pdf

Full prescribing information for Xibrom™ is available on ISTA Pharmaceuticals' website at http://www.istavision.com/pdf/XibromPI_XIB553.pdf

Full prescribing information for Istalol® is available on ISTA Pharmaceuticals' website at www.istavision.com/pdf/Istalol_Full_PI-ISL274.pdf

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is the fourth largest branded ophthalmic pharmaceutical business in the U.S. ISTA's four marketed products plus its product candidates include therapies for inflammation, ocular pain, allergy, glaucoma, and dry eye. The Company is developing a strong product pipeline to fuel future growth and market share, supporting its goal to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com/.

ISTA has no obligation or intention to release preliminary results in subsequent quarters.

SOURCE ISTA Pharmaceuticals, Inc.

RELATED LINKS
http://www.istavision.com

'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diffusion Pharmaceuticals LLC Closes on $5.9 Million Financing
2. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
3. Intercept Pharmaceuticals Raises $25 Million Series B Financing
4. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
5. Amylin Pharmaceuticals to Webcast Year-End Financial Results
6. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
7. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
8. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
9. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
10. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
11. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... MUMBAI , March 23, 2017 ... de Piramal Enterprises Limited, anuncia el nombramiento de ... PPS ofrece una plataforma de servicios integrados completa ... Needleman desempeñará un cargo clave en el crecimiento ... comercial, Needleman será responsable de impulsar todas las ...
(Date:3/23/2017)... 23, 2017  Galmed Pharmaceuticals Ltd. (Nasdaq: ... clinical-stage biopharmaceutical company focused on the development of ... nonalcoholic steatohepatitis, or NASH, and other liver diseases, ... twelve months ended December 31, 2016, and announced new ... demonstrating Aramchol™,s potential direct effect on liver fibrosis. ...
(Date:3/23/2017)... 23, 2017 ReNeuron reported in December ... in chronic stroke patients, despite not meeting the three-month time ... the Action Research Arm Test (ARAT). As a result, the ... controlled clinical study in 2017. Beyond CTX, we expect safety ... 2017 and Phase I data from its critical limb ischaemia ...
Breaking Medicine Technology:
(Date:3/23/2017)... Yardley, PA (PRWEB) , ... March 23, 2017 ... ... received Patient Oriented Disease Management Accreditation from the NCQA. The accreditation covers StayWell’s ... programs. , Accredited status is granted to organizations that have excellent programs ...
(Date:3/23/2017)... ... , ... The TouchPoint Solution, home of Buzzies *, is boosting the ... , “Buzzies change the way we interact with stress and live our day-to-day lives,” ... date in December 2016, The TouchPoint Solution has sold more than $750,000 in product ...
(Date:3/23/2017)... , ... March 23, 2017 , ... After raising more ... FaceCradle , the most-funded travel pillow in crowdfunding history, has established a ... its wildly popular travel innovation to Americans. , “We’re excited to be operating on ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced rapid completion of the strategic executive team expansion needed to further ... to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, ... aspects of people’s health and nutrition, announced its product Leyzene is now available ... Subsistence develops nutritional supplements that help people improve all aspects of their health ...
Breaking Medicine News(10 mins):